Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Saved in:
| Title: | Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. |
|---|---|
| Authors: | Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Stein Gold L; Henry Ford Hospital, Detroit, MI, USA., Papp K; Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada., Han G; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Pariser DM; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA., Lin T; Ortho Dermatologics†, Bridgewater, NJ, USA., Harris S; Bausch Health US, LLC†, Bridgewater, NJ, USA., Jacobson A; Ortho Dermatologics†, Bridgewater, NJ, USA. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 May; Vol. 35 (5), pp. 1152-1160. Date of Electronic Publication: 2021 Feb 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33428282 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Lebwohl+MG%22">Lebwohl MG</searchLink>; Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Stein+Gold+L%22">Stein Gold L</searchLink>; Henry Ford Hospital, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Papp+K%22">Papp K</searchLink>; Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Han+G%22">Han G</searchLink>; Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Pariser+DM%22">Pariser DM</searchLink>; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA.<br /><searchLink fieldCode="AU" term="%22Lin+T%22">Lin T</searchLink>; Ortho Dermatologics†, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Harris+S%22">Harris S</searchLink>; Bausch Health US, LLC†, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Jacobson+A%22">Jacobson A</searchLink>; Ortho Dermatologics†, Bridgewater, NJ, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229216037%22">Journal of the European Academy of Dermatology and Venereology : JEADV</searchLink> [J Eur Acad Dermatol Venereol] 2021 May; Vol. 35 (5), pp. 1152-1160. <i>Date of Electronic Publication: </i>2021 Feb 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9216037 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1468-3083 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209269959%22">09269959 </searchLink><i>NLM ISO Abbreviation: </i>J Eur Acad Dermatol Venereol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33428282 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/jdv.17113 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1152 Titles: – TitleFull: Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lebwohl MG – PersonEntity: Name: NameFull: Stein Gold L – PersonEntity: Name: NameFull: Papp K – PersonEntity: Name: NameFull: Han G – PersonEntity: Name: NameFull: Pariser DM – PersonEntity: Name: NameFull: Lin T – PersonEntity: Name: NameFull: Harris S – PersonEntity: Name: NameFull: Jacobson A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2021 May Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1468-3083 Numbering: – Type: volume Value: 35 – Type: issue Value: 5 Titles: – TitleFull: Journal of the European Academy of Dermatology and Venereology : JEADV Type: main |
| ResultId | 1 |
